Plitidepsin (Synonyms: Aplidine; PM90001)

Name: Plitidepsin
Brand: MedChemExpress
SKU: HY-16050
Rating: 5.0 (2 reviews)

Cat. No.: HY-16050 Purity: 99.80%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Plitidepsin (Aplidine) is a potent anti-cancer agent by targeting eEF1A2 ( K_D=80 nM). Plitidepsin possesses antiviral activity and is against SARS-CoV-2 with an IC₉₀ of 0.88 nM. Plitidepsin is usually used for multiple myeloma and advanced cancer research, and has the potential for COVID-19 research.

For research use only. We do not sell to patients.

Plitidepsin Chemical Structure

CAS No. : 137219-37-5

Size	Price	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 1221	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 1221	In-stock	Estimated Time of Arrival: December 31
Solid
1 mg	USD 300	In-stock	Estimated Time of Arrival: December 31
5 mg	USD 750	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 1000	In-stock	Estimated Time of Arrival: December 31
25 mg	USD 1580	In-stock	Estimated Time of Arrival: December 31
50 mg	USD 2000	In-stock	Estimated Time of Arrival: December 31
100 mg	USD 3400	In-stock	Estimated Time of Arrival: December 31
200 mg		Get quote
500 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 2 publication(s) in Google Scholar

Other Forms of Plitidepsin:

Plitidepsin (Standard) Get quote

2 Publications Citing Use of MCE Plitidepsin

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

Plitidepsin (Aplidine) is a potent anti-cancer agent by targeting eEF1A2 ( K_D=80 nM)^[1]. Plitidepsin possesses antiviral activity and is against SARS-CoV-2 with an IC₉₀ of 0.88 nM. Plitidepsin is usually used for multiple myeloma and advanced cancer research, and has the potential for COVID-19 research^[1]^[2].

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	0.2 nM Compound: 2	Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 3 days Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 3 days	[PMID: 33592144]
HT-29	IC₅₀	0.5 nM Compound: 2	Antiproliferative activity against human HT-29 cells assessed as cell growth inhibition incubated for 3 days Antiproliferative activity against human HT-29 cells assessed as cell growth inhibition incubated for 3 days	[PMID: 33592144]
P388	IC₅₀	> 1 μM Compound: 2	Inhibition of RNA synthesis in mouse P388 cells measured after 72 hrs Inhibition of RNA synthesis in mouse P388 cells measured after 72 hrs	[PMID: 33592144]
P388	IC₅₀	0.1 μM Compound: 2	Inhibition of DNA synthesis in mouse P388 cells measured after 72 hrs Inhibition of DNA synthesis in mouse P388 cells measured after 72 hrs	[PMID: 33592144]
P388	IC₅₀	0.2 nM Compound: 2	Antiproliferative activity against mouse P388 cells assessed as cell growth inhibition incubated for 3 days Antiproliferative activity against mouse P388 cells assessed as cell growth inhibition incubated for 3 days	[PMID: 33592144]
P388	IC₅₀	0.5 μM Compound: 2	Inhibition of protein synthesis in mouse P388 cells measured after 72 hrs Inhibition of protein synthesis in mouse P388 cells measured after 72 hrs	[PMID: 33592144]
SK-MEL-28	IC₅₀	0.5 nM Compound: 2	Antiproliferative activity against human SK-MEL-28 cells assessed as cell growth inhibition incubated for 3 days Antiproliferative activity against human SK-MEL-28 cells assessed as cell growth inhibition incubated for 3 days	[PMID: 33592144]

In Vitro

Plitidepsin (20 nM; 1 h) induces a dose-dependent decrease in VEGF secretion in MOLT-4 cells^[1].
? Plitidepsin (20 nM; 1 h) does not result in significant inhibition of VEGF-R1 mRNA in normal endothelial cells, which do express VEGFR-1 but do not secrete VEGF^[1].
? Plitidepsin inhibits SARS-CoV-2 with an IC₉₀?of 1.76 nM. In hACE2-293T cells, Plitidepsin exhibits anti–SARS-CoV-2 activity with an IC₉₀ of 0.88 nM. In an established model of human pneumocyte-like cells, Plitidepsin inhibits SARS-CoV-2 replication with an IC₉₀?of 3.14 nM and a selectivity index of 40.4^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Plitidepsin (intraperitoneal?injection; 0.3 mg/kg or 1 mg/kg; 2 hours before infection with SARS-CoV-2) significantly reduces SARS-CoV-2 infection in BALB/c mice expressing human ACE2. 0.3 mg/kg plitidepsin group results in a reduction of nearly 2 log units in SARS-CoV-2 viral titers in the lungs, and the 1 mg/kg group leads to? a reduction of 1.5 log units relative to the vehicle control group^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	BALB/c mice^[1]
Dosage:	0.3 mg/kg; 1 mg/kg
Administration:	1 day QD at 1 mg/kg; 3days QD at 0.3 mg/kg
Result:	Showed in vivo antiviral efficacy in mouse models of SARS-CoV-2 infection.

Clinical Trial

Molecular Weight

1110.34

Formula

C₅₇H₈₇N₇O₁₅

CAS No.

137219-37-5

Appearance

Solid

Color

White to off-white

SMILES

O=C([C@@H](NC([C@H](C([C@@H](OC(C[C@@H]1O)=O)C(C)C)=O)C)=O)CC(C)C)N(CCC2)[C@]2([H])C(N([C@H](C(O[C@@H]([C@@H](C(N[C@]1([H])[C@@H](C)CC)=O)NC([C@@H](CC(C)C)N(C)C([C@H](CCC3)N3C(C(C)=O)=O)=O)=O)C)=O)CC(C=C4)=CC=C4OC)C)=O

Initial Source

Microorganisms

Mediterranean tunicate Aplidium albicans

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Sealed storage, away from moisture and light, under nitrogen

Powder	-80°C	2 years
	-20°C	1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (90.06 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	0.9006 mL	4.5031 mL	9.0063 mL
5 mM	0.1801 mL	0.9006 mL	1.8013 mL
10 mM	0.0901 mL	0.4503 mL	0.9006 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.5 mg/mL (2.25 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (2.25 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.80%

Select Batch:

Data Sheet (287 KB) SDS (252 KB)

COA (268 KB) HNMR (316 KB) RP-HPLC (268 KB) MS (72 KB)

Handling Instructions (2659 KB)

References

[1]. Alejandro Losada, et al. Translation Elongation Factor eEF1A2 is a Novel Anticancer Target for the Marine Natural Product Plitidepsin. Sci Rep. 2016 Oct 7;6:35100. [Content Brief]

[2]. Kris M White, et al. Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A. Science. 2021 Feb 26;371(6532):926-931. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	0.9006 mL	4.5031 mL	9.0063 mL	22.5156 mL
	5 mM	0.1801 mL	0.9006 mL	1.8013 mL	4.5031 mL
	10 mM	0.0901 mL	0.4503 mL	0.9006 mL	2.2516 mL
	15 mM	0.0600 mL	0.3002 mL	0.6004 mL	1.5010 mL
	20 mM	0.0450 mL	0.2252 mL	0.4503 mL	1.1258 mL
	25 mM	0.0360 mL	0.1801 mL	0.3603 mL	0.9006 mL
	30 mM	0.0300 mL	0.1501 mL	0.3002 mL	0.7505 mL
	40 mM	0.0225 mL	0.1126 mL	0.2252 mL	0.5629 mL
	50 mM	0.0180 mL	0.0901 mL	0.1801 mL	0.4503 mL
	60 mM	0.0150 mL	0.0751 mL	0.1501 mL	0.3753 mL
	80 mM	0.0113 mL	0.0563 mL	0.1126 mL	0.2814 mL

Plitidepsin Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Product Name

Salutation

Applicant Name *

Email Address *

Phone Number *

Organization Name *

Department *

Requested quantity *

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Plitidepsin (Synonyms: Aplidine; PM90001)

Customer Review

Other Forms of Plitidepsin:

Plitidepsin Related Antibodies

2 Publications Citing Use of MCE Plitidepsin

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity

Purity & Documentation

References

Customer Review

Plitidepsin Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Plitidepsin Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report